Abstract: BACKGROUND Regorafenib is the first small-molecule multikinase inhibitor which showed survival benefits in pretreated metastatic colorectal cancer (mCRC) patients. Beside classical adverse events of this drug class, hepatotoxicity has been described as a frequent side effect. MATERIAL AND METHODS Patients with refractory mCRC treated with regorafenib in our institution were reviewed. Severe treatment-related liver toxicity was investigated. Clinical history, liver histology and genetic assessment (sequence analysis) of cytochrome P 3A4 (CYP3A4) and uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) involved in regorafenib metabolization were here reported for patients with severe hepatotoxicity. RESULTS Among the 93 reviewed patients, 3 presented severe and icteric toxic hepatitis which was fatal for 1 patient. Histopathological liver lesions were different depending on the onset of hepatotoxicity (acute or subacute): acinar zone 3 necrosis in case of acute symptoms and portal tract inflammation with porto-central bridging and fibrosis in the delayed presentation. None patients had CYP3A4 gene mutations. Similar polymorphisms in UGT1A9 gene promoter region (UGT1A9 variant -118T9>10 (rs3832043)) were found in both patients who presented acute hepatitis. Moreover, it appears retrospectively that both of them already experienced significant toxicity under irinotecan-based chemotherapy. CONCLUSION This is the first report of severe hepatotoxicity with available liver histology and genetic assessment of enzymes involved in regorafenib metabolization. This report also reminds the importance of a close liver tests monitoring during regorafenib treatment. This article is protected by copyright. All rights reserved. 
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KEY POINTS
-Regorafenib showed survival benefits in pretreated metastatic colorectal and is widely used.
-Hepatotoxicy is a frequent side effect, severe liver injury is rare but grave.
-Histopathological lesions of severe liver injury show acinar zone 3 necrosis in case of acute onset and portal tract inflammation with porto-central bridging and fibrosis in the delayed presentation.
-Genetic assessment of UGT1A9 and CYP3A4 (gene involved in regorafenib metabolization) reveals similar polymorphisms in UGT1A9 gene promoter region (UGT1A9 variant -118T 9>10 (rs3832043)) associated with the acute form presentation. Beside classical adverse events (fatigue, hypertension, hand-foot skin reaction and diarrhea), hepatotoxicity has been described as a side effect. In the CORRECT study, Common Toxicity Criteria (4.0) for Adverse Event (CTCAE) grade ≥3 hyperbilirubinemia was observed in 2% patients, and no other adverse events associated with liver dysfunction were reported. In the CONCUR study (Asian population only), liver dysfunction was more frequent with grade ≥3 hyperbilirubinemia, alanine aminotransferase (ALT) and aspartate
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aminotransferase (AST) elevation of 7%, 7% and 6% respectively [2] . As the mechanism of this liver toxicity remains unclear, we focused here on hepatotoxicity occurring during regorafenib treatment to extensively characterize severe case of patients with liver injury.
MATERIAL AND METHODS
Patients with refractory mCRC treated with regorafenib (160 mg/day 3 weeks on each 4 week cycle) in the Cliniques Universitaires Saint-Luc between January 2011 and June 2015 were reviewed. All these patients gave their consent to be treated in clinical trial [1] or in early access program before regorafenib was accessible in Belgium. Our objective was to describe the occurrence of severe treatment-related liver toxicity defined by at least an increase of bilirubin and ALT / AST to a grade 3 or 4 (CTCAE v4.0). We report here the detailed clinical history, liver function tests (LFT) and liver histology (biopsy) of identified patients. Given the hepatic metabolism of regorafenib via cytochrome P 3A4 (CYP3A4) and uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9), the most frequent mutations in both genes assessed by sequence analysis were also analyzed and reported. Approval for this research was obtained from the ethic committees of the Cliniques Universitaires Saint-Luc
RESULTS
Among the 93 patients treated with regorafenib, transient CTCAE grade 1-2 hyperbilirubinemia, ALT and AST elevation were observed during the first 2 cycles (2 months) in 21 patients (22.5%), 10 patients (10.7%) and 11 patients (11.8%) respectively. All patients had normal LFT (bilirubin, ALT and AST) before treatment.
Accepted Article
This article is protected by copyright. All rights reserved. 
(N 70-110). Other daily medications were simvastatin, bisoprolol, apixaban and lisinopril, all of these having been introduced more than 6 months ago. Regorafenib and all other treatments were stopped. Viral and auto-immune serological tests were negative except for a low non-specific antinuclear antibody positivity in the absence of IgG increase (Supplementary Table 1 were preserved and inflammation was scarce (Fig. 1A) . Immunohistochemical (IHC) and molecular tests were negative for hepatitis E virus (HEV) (Supplementary Table 2 Autoimmune and viral serologies were negative (Supplementary Table 1) . No others hepatotoxic drugs were taken. Regorafenib was withdrawn and high dose intravenous acetylcysteine was administered. A transjugular liver biopsy was performed. The hepatovenous gradient was 4 mmHg. Liver histology showed severe portal tract inflammation
with porto-central bridging, fibrosis and hepatocytes loss in the central area (Fig. 1B) . IHC and molecular testings were negative for HEV (Supplementary Table 2 ). LFT progressively improved with normalisation within 2 months after stopping the treatment. Patient died from progressive tumoral disease 6 months after fully recovered of this complication.
Given the hepatic metabolism of regorafenib via CYP3A4 and UGT1A9, the most frequent mutations in both 2 genes were assessed by sequence analysis. Patient 1 and patient 2 carried similar genetic polymorphisms in the UGT1A9 gene promoter region. Both were heterozygous for UGT1A9*22 allele (UGT1A29 variant -118T 9>10 ; rs3832043), characterized by a single base insertion of thymidine. Moreover, a heterogenous and homogenous intronic transversion (C>T) were identified in patients 1 and 2 respectively.
UGT1A9 sequencing did not show any mutation in patient 3. Regarding the CYP3A4 gene, no mutation was discovered in any of the patients.
Patients' characteristics are summarized in Table 1 .
DISCUSSION
The introduction of small-molecule TKIs in clinical oncology has transformed the treatment of certain forms of cancers. Unexpectedly, their use has been found to be associated with serious toxic effects on a number of vital organs including the liver. Indeed, hepatotoxicity in cancer patients treated with TKI is well reported and justifies close monitoring: a meta-analysis demonstrated a significant increase of developing high-grade hepatotoxicity with TKIs use [3] [4] .
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The regorafenib safety profiles were initially limited before investigators decided to proceed to a phase III trial due to positive signals observed in phase I [5] . Although less predictable, elevated LFT were also frequent and generally occurred soon after treatment initiation. Therefore, monitoring of bilirubin and transaminases was considered as crucial during the first two cycles in order to allow early discontinuation in case of liver abnormalities. Severe drug-induced liver injury (DILI) led to fatal outcome in only 0.3% of 1100 regorafenib-treated patients across all clinical trials [6] and all patients presenting with hepatic failure also had liver metastases.
In our trial, the proportion of patients with grade 1-2 increased bilirubin or aminotransferases was higher as reported in the CORRECT trial [1] . Here, we reported severe hepatoxicity for 3 patients including one patient with fatal outcome. We distinguish two clinical histories of hepatitis, each of them associated with different histopathological patterns. In patient 3, biochemical abnormalities and symptoms appeared several months after initiation of the treatment, and liver biopsy showed features of severe active hepatitis with portal inflammation, bridging fibrosis, reminding of auto-immune hepatitis. By contrast, in patient 2, we found centrilobular necrosis, a morphological abnormality seen in acute acetaminophen toxicity, whose mechanism is also linked to the P-450 cytochrome system.
Regorafenib is a major substrate of CYP3A4, a factor described as an important predictor of DILI [7] . Furthermore, given its exclusive liver metabolism, regorafenib is a medication at higher risk for DILI [8] . In the patient 2 case, regorafenib was coadministred with three other CYP3A4 substrates (simvastatin, bisoprolol and apixaban) but all of them were already introduced since several months. Considering that more than one substrate can
bind to the active enzyme site of CYP3A4 [9] and the clear evidence for cooperativity in substrate binding and in catalytic turnover [10] , the influence of other CYP3A4 substrates on regorafenib metabolism could have been a factor contributing to the severe toxicity observed in patient 2.
UGT1A9 is the second enzyme implicated in regorafenib metabolism. Over the last decade, polymorphism in UGT1A superfamily has been widely studied, particularly in order to predict interindividual toxicity of irinotecan [11] . Moreover, a recent Chinese study
showed an association between UGT1A9 promoter polymorphisms (T>C transition; position−440 (rs2741045)) and DILI [12] but no pieces of evidence demonstrated so far the functional impact of -118T 9>10 polymorphism on interindividual variation in hepatic UGT1A9 activity and mRNA expression [13] . In the present report, it is of note that both patients presenting with acute hepatic dysfunction exhibited similar polymorphisms (variant -118T 9>10 ) in UGT1A9 gene promoter region. Retrospectively, it appears that both of them experienced intolerance under irinotecan-based chemotherapy requiring fast dose reduction:
grade 3 neutropenia during the first cycle for patient 1 and grade 3 neutropenia and diarrhea for patient 2.
Our report remains descriptive with several limitations that cannot confirm the definitive role of UGT1A9 polymorphisms in regorafenib hepatotoxicity (and a possible cross-toxicity with irinotecan). Indeed, UGT1A9 genotyping was only performed in the 3 patients with severe liver injury and not in the remaining cohort. Moreover, the reported high frequency (up to 39% of patients) and lack of interindividual liver activity variation of the -118T 9>10 polymorphism justifies caution and further reports before any conclusion.
Another limitation is the absence of histology available for patient 1. However, acute presentation following regorafenib introduction and return to normal after treatment cessation
are in favor of DILI. HEV is a relevant differential diagnosis to DILI. Since patient's residual sera were not available, we applied combined IHC and molecular testing for HEV on liver biopsies and found no evidence for a HEV infection (Supplementary Table 2 ).
To our knowledge, this is the first report of severe hepatotoxicity with available liver histology and genetic assessment of enzymes involved in regorafenib metabolization.
Conversely to the published case-reports [14] [15] [16] , one of our patients died from liver failure.
LFT from others patients improved with normalisation as described in these reports.
Furthermore, our patients had no previous history of liver dysfunction. Both of these arguments advocate a direct toxicity of the multikinase inhibitor without predisposing liver condition.
In summary, this report highlights the importance of a close liver monitoring during regorafenib treatment, especially during the first cycles. Nevertheless, even if infrequent, delayed hepatic toxicity can occur. It illustrates also that severe hepatotoxicity is not limited to patients presenting with liver metastases. Whereas the mechanism of toxicity remains so far unclear, further reports are needed to explore the role of CYP3A4 and UGT1A9 polymorphisms and hepatic activities and the possible cross-toxicity with irinotecan...
